noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

U.S. Department of Education

U.S. Department of Education Finalizes Landmark Rule to Lower College[...]
Nepra Foods Inc.

Nepra Foods Enters Letter of Intent to Acquire Idaho Bottling and Water[...]
EPA - U.S. Environmental[...]

Trump EPA announces $697,000,000 to protect South Carolina waterways[...]

Healthcare

Fibrobiologics Inc.

04/30/2026 | Press release | Distributed by Public on 04/30/2026 06:45

FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026

April 30, 2026 8:30am EDT Download as PDF

HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the presentation of preclinical data from its CYPS317 program for psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting taking place May 13-15, 2026, in Chicago, Illinois.

Details of the presentations are as follows:
Event: Society for Investigative Dermatology 2026 Annual Meeting
Presenter: Chuo Fang, MD, Ph.D., Senior Scientist at FibroBiologics
Session Date and Time: 4:30 p.m. - 6 p.m. CT on May 15, 2026
Location: Salons B, C, D; Williford - 3^rd Floor

For more information, please visit FibroBiologics' website, email FibroBiologics at [email protected] or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.

About FibroBiologicsBased in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit https://www.FibroBiologics.com.

General Inquiries:[email protected]

Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
[email protected]

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
[email protected]

Source: FibroBiologics, Inc.

Released April 30, 2026

Fibrobiologics Inc. published this content on April 30, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 30, 2026 at 12:45 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]